”It’s a top five deal”
Bavarian Nordic and the company’s CFO are more than pleased with the deal the company struck with Bristol-Myers Squibb this Wednesday concerning its cancer candidate Prostvac – both in terms of economy, opportunities and the specific partner.
BY STEFAN SINGH KAILAY
“It’s a huge deal; it’s the biggest deal in the history of our company. It’s validation from Big Pharma of the second of our two technology platforms. The first validation came with the deal with Johnson & Johnson for our MVA platform.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bavarian strikes historic Prostvac deal
For abonnenter
Bavarian: Most compelling results so far
For abonnenter
